Online inquiry

IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5747MR)

This product GTTS-WQ5747MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5747MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5333MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ10148MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ9755MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ461MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ11072MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ6694MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ13348MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ11627MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW